#ACC22 – RCT: Edoxaban vs. dual antiplatelet therapy for preventing leaflet thrombosis and cerebral thromboembolism after TAVR.

Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial – Circulation

Commentary:

No reduction in stroke, mini strokes, blood clotting or changes in cognitive function with edoxaban after TAVR – American College of Cardiology

ADAPT-TAVR: Edoxaban vs. DAPT in Reducing SLT and Cerebral Thromboembolism After TAVR – American College of Cardiology

Related:

M-A: Single antiplatelet therapy should be used after transcatheter aortic valve implantation in patients without indication for anticoagulation.

M-A: Aspirin alone better than dual antiplatelet therapy after transcatheter aortic valve implantation

#ESCCongress – [Abstract Only] Randomized trial: aspirin with or without clopidogrel after transcatheter aortic-valve implantation

#ACC21 – [Not published yet] RCT: Among patients undergoing TAVR, full-dose apixaban is not superior to standard of care (vitamin K antagonist if indication for oral anticoagulation; antiplatelet therapy if no indication).

#AHA19 – [Abstract Only] Randomized Trial: An Antiplatelet-based Strategy is Associated with Better Outcomes vs. Anticoagulation After Transcatheter Aortic-Valve Replacement

Commentary on Twitter

Findings from ADAPT-TAVR at #ACC22 suggest no statistical difference between edoxaban or #DAPT in reducing the incidence of subclinical leaflet thrombosis or new cerebral thromboembolism. Read more: https://t.co/W5dbJraDdi #TAVR #ACCIntl pic.twitter.com/wu3QP85GaE

— American College of Cardiology (@ACCinTouch) April 4, 2022